JCR Pharmaceuticals Co.,Ltd. [4552.T]
TOKYO, Jan 28 (Pulse News Wire) – JCR Pharmaceuticals CO.,LTD. (4552.T) reported a special gain of ¥1.882 billion in its third quarter ended December 31, 2025.
The gain was attributed to the confirmation of government grants related to the construction of the Kobe Science Park Center's pharmaceutical plant. Specifically, the company recognized the grant amount, adjusted for depreciation and unused funds, previously recorded in deferred revenue accounts. In addition to the special gain, JCR Pharma noted the impact on its operating results.
Detailed figures for the quarter, including the effect of this special item, were disclosed in the company’s interim report released today. Investors should review the “2026 March Term Third Quarter Condensed Financial Results” for further insights into the company’s performance during the period. The company did not provide additional commentary beyond the financial statement release, focusing solely on the quantitative aspects of the special gain and its implications for the quarterly earnings.
🟡 Confidence: Standard AI-translated content.